Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a report released on Friday. The brokerage set a “sell” rating on the stock.

Bio-Path Stock Up 4.8 %

Bio-Path stock opened at $0.91 on Friday. The stock has a 50-day simple moving average of $1.00 and a 200 day simple moving average of $1.67. Bio-Path has a 12-month low of $0.80 and a 12-month high of $12.43.

Bio-Path (NASDAQ:BPTH) last released its quarterly earnings results on Thursday, August 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.38. During the same period in the prior year, the firm earned ($10.60) earnings per share. Sell-side analysts anticipate that Bio-Path will post -6.2 EPS for the current year.

Institutional Trading of Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC acquired a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path as of its most recent SEC filing. 5.74% of the stock is owned by hedge funds and other institutional investors.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.